翰森制药:奥拉托肽注射液新药上市申请获中国国家药监局受理 用于慢性体重管理

美股速递
Jun 04

翰森制药宣布,其用于慢性体重管理的创新药奥拉托肽注射液的新药上市申请,已获得中国国家药品监督管理局的受理。

此次受理标志着该药物在中国商业化进程中的关键一步。若最终获批,奥拉托肽注射液将为国内慢性体重管理领域提供新的治疗选择。

公司表示将继续与监管机构保持密切沟通,积极推进后续审评工作。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10